These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38692939)

  • 21. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesenchymal stromal cells protect human cardiomyocytes from amyloid fibril damage.
    Lin Y; Marin-Argany M; Dick CJ; Redhage KR; Blancas-Mejia LM; Bulur P; Butler GW; Deeds MC; Madden BJ; Williams A; Wall JS; Dietz A; Ramirez-Alvarado M
    Cytotherapy; 2017 Dec; 19(12):1426-1437. PubMed ID: 29037943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissection of the amyloid formation pathway in AL amyloidosis.
    Kazman P; Absmeier RM; Engelhardt H; Buchner J
    Nat Commun; 2021 Nov; 12(1):6516. PubMed ID: 34764275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis.
    Puri S; Schulte T; Chaves-Sanjuan A; Mazzini G; Caminito S; Pappone C; Anastasia L; Milani P; Merlini G; Bolognesi M; Nuvolone M; Palladini G; Ricagno S
    J Mol Biol; 2023 Sep; 435(18):168215. PubMed ID: 37516426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
    PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
    Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
    J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis.
    Morgan GJ
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34208058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualized Approach to Management of Light Chain Amyloidosis.
    Palladini G; Milani P
    J Natl Compr Canc Netw; 2023 Jan; 21(1):91-98. PubMed ID: 36634608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
    Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
    J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Al amyloidosis.
    Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
    Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid fibril structure from the vascular variant of systemic AA amyloidosis.
    Banerjee S; Baur J; Daniel C; Pfeiffer PB; Hitzenberger M; Kuhn L; Wiese S; Bijzet J; Haupt C; Amann KU; Zacharias M; Hazenberg BPC; Westermark GT; Schmidt M; Fändrich M
    Nat Commun; 2022 Nov; 13(1):7261. PubMed ID: 36433936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
    Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
    J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
    Del Giudice ML; Galimberti S; Buda G
    Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis.
    Palladini G; Liedtke M; Zago W; Dolan P; Kinney GG; Gertz MA
    Leuk Lymphoma; 2024 Aug; 65(8):1068-1078. PubMed ID: 38600883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoglobulin-related (AL) amyloidosis.
    Husby G
    Clin Exp Rheumatol; 1983; 1(4):353-8. PubMed ID: 6442636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
    Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
    Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury.
    Crees ZD; Stockerl-Goldstein K
    Am J Med; 2022 Apr; 135 Suppl 1():S49-S52. PubMed ID: 35081378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.